A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Trial Profile

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Nivolumab (Primary) ; NKTR 214 (Primary) ; NKTR-262 (Primary)
  • Indications Breast cancer; Colorectal cancer; Malignant melanoma; Merkel cell carcinoma; Ovarian cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 21 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 01 Mar 2018 According to Nektar Therapeutics media release, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NKTR-262 on December 2017 and company plans to enroll the first patient in this study in March of 2018.
    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top